Stifel Maintains Buy on Regenxbio, Maintains $40 Price Target
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Annabel Samimy maintains a Buy rating on Regenxbio (NASDAQ:RGNX) with a maintained price target of $40.
April 12, 2024 | 3:53 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Stifel analyst Annabel Samimy reaffirms a Buy rating on Regenxbio with a $40 price target.
The reaffirmation of a Buy rating and a $40 price target by a Stifel analyst suggests a positive outlook on Regenxbio's stock. This endorsement could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100